Zeaxanthin

Zeaxanthin
Product Name Zeaxanthin
CAS No.: 144-68-3
Catalog No.: CFN90234
Molecular Formula: C40H56O2
Molecular Weight: 568.88 g/mol
Purity: >=98%
Type of Compound: Miscellaneous
Physical Desc.: Powder
Targets: Immunology & Inflammation related
Source: The fruits of Zea mays L.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price:
Lutein and Zeaxanthin in neural tissue may have biological effects that include antioxidation, anti-inflammation, and structural actions. Lutein and Zeaxanthin may be protective against eye disease because they absorb damaging blue light that enters the eye.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Int J Pharmacol2020, 16:1-9
  • J Biotechnol.2020, 318:10-19.
  • Arch Biochem Biophys.2020, 687:108384.
  • Nutrients.2019, 11(4):E936
  • Antioxidants (Basel).2020, 9(4):326.
  • Mol Neurobiol.2023, 60(12):7196-7207.
  • Int J Biol Macromol.2018, 112:1093-1103
  • Journal of Life Science2017, 233-240
  • ACS Synth Biol.2022, 11(10):3296-3304.
  • Acta Pharmaceutica Hungarica2016, 86:35-40
  • beta-Cryptoxanthin

    Catalog No: CFN70370
    CAS No: 472-70-8
    Price: Inquiry(manager@chemfaces.com)
    Capsanthin

    Catalog No: CFN70366
    CAS No: 465-42-9
    Price: Inquiry(manager@chemfaces.com)
    Astaxanthin

    Catalog No: CFN90096
    CAS No: 472-61-7
    Price: $138/20mg
    Lutein

    Catalog No: CFN99384
    CAS No: 127-40-2
    Price: $80/20mg
    Helenien

    Catalog No: CFN70406
    CAS No: 547-17-1
    Price: Inquiry(manager@chemfaces.com)
    Zeaxanthin

    Catalog No: CFN90234
    CAS No: 144-68-3
    Price: Inquiry(manager@chemfaces.com)
    Physalien

    Catalog No: CFN70273
    CAS No: 144-67-2
    Price: Inquiry(manager@chemfaces.com)
    alpha-Carotene

    Catalog No: CFN93610
    CAS No: 7488-99-5
    Price: Inquiry(manager@chemfaces.com)
    Beta-Carotene

    Catalog No: CFN98117
    CAS No: 7235-40-7
    Price: $40/20mg
    Fucoxanthin

    Catalog No: CFN90852
    CAS No: 3351-86-8
    Price: $318/20mg
    Mol Vis . 2019 Sep 5;25:479-488. eCollection 2019.
    Evaluation of antioxidant treatments for the modulation of macrophage function in the context of retinal degeneration[Pubmed: 31588172]
    Abstract Purpose: Oxidative stress and macrophages have been implicated in the pathogenesis of atrophic and neovascular age-related macular degeneration (aAMD and nvAMD). It is unclear whether oxidative injury mediates macrophage involvement in AMD. We aimed to investigate the effect of antioxidant treatments on human monocyte-derived macrophages (hMDMs) from patients with AMD in models for the disease. Methods: Four antioxidant treatments were evaluated (G1: lutein + Zeaxanthin, G2: lutein + Zeaxanthin and zinc, G3: lutein + Zeaxanthin, zinc, Lyc-O-Mato, and carnosic acid, G4: lutein + Zeaxanthin, carnosic acid, and beta-carotene, G5: olive oil as vehicle control). The compounds were added to the culture medium of M1 (interferon-gamma [IFN-Ɣ] and lipopolysaccharide [LPS]) and M2a (interleukin-13 [IL-13] and IL-4) hMDMs from patients with AMD (n=7 and n=8, respectively). Mouse choroidal tissue was cultured with supernatants from treated M1/M2a hMDMs, to evaluate the effect of treatments on the angiogenic properties of macrophages with choroidal sprouting assay (CSA). Mouse retinal explants were cultured with treated hMDMs for 18 h, and evaluated for photoreceptor apoptosis using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) labeling. Adult BALB/c mice (n=8) were exposed to 8,000 lux bright light for 3 h, and treated orally with antioxidant supplements for 7 days that preceded light injury and following it. Oxidative stress was assessed using an anti-4 hydroxynonenal (4-HNE) antibody. Retinal function and the thickness of the outer nuclear layer were evaluated with electroretinography (ERG) and histological analysis, respectively. Results: The G3 treatment reduced M2a hMDMs-associated sprouting in the CSA compared to the untreated group (n=7, -1.52-fold, p=0.05). Conversely, the G2 treatment was associated with an increased neurotoxic effect of M2a hMDMs in the retinal explant assay compared to the control group (n=7, 1.37-fold, p=0.047), as well as compared to the G3 treatment group (1.46-fold, p=0.01). The G4 treatment was also associated with increased cytotoxicity compared to the control group (1.48-fold, p=0.004), and compared to the G3 treatment group (1.58-fold, p=0.001). In the in vivo light damage model, mice (n=8) supplemented with G2, G3, and G4 had decreased levels of oxidative injury assessed using 4-HNE labeling (-2.32-fold, -2.17-fold, and -2.18-fold, respectively, p<0.05 for all comparisons). None of the treatments were associated with reduced photoreceptor cell loss, as shown with histology and ERG. Conclusions: Antioxidant treatment modulates M2a hMDMs at the functional level. In particular, we found that the G3 combination has a beneficial effect on M2a macrophages in reducing their angiogenic and neurotoxic capacity ex vivo. In addition, antioxidant treatments considerably reduced the oxidative stress level in light-damaged retinas. Further research is required to assess whether such therapies may curb macrophage-driven photoreceptor loss and neovascularization in AMD.
    Arch Biochem Biophys. 2015 Apr 15;572:54-7.
    A randomized placebo-controlled study on the effects of lutein and zeaxanthin on visual processing speed in young healthy subjects.[Pubmed: 25483230]
    Speed of processing is a particularly important characteristic of the visual system. Often a behavioral reaction to a visual stimulus must be faster than the conscious perception of that stimulus, as is the case with many sports (e.g., baseball). Visual psychophysics provides a relatively simple and precise means of measuring visual processing speed called the temporal contrast sensitivity function (tCSF). Past study has shown that macular pigment (a collection of xanthophylls, lutein (L), meso-Zeaxanthin (MZ) and Zeaxanthin (Z), found in the retina) optical density (MPOD) is positively correlated with the tCSF.
    METHODS AND RESULTS:
    In this study, we found similar correlations when testing 102 young healthy subjects. As a follow-up, we randomized 69 subjects to receive a placebo (n=15) or one of two L and Z supplements (n=54). MPOD and tCSF were measured psychophysically at baseline and 4months. Neither MPOD nor tCSF changed for the placebo condition, but both improved significantly as a result of supplementation.
    CONCLUSIONS:
    These results show that an intervention with L and Z can increase processing speed even in young healthy subjects.
    Food Chem Toxicol. 2014 Oct;72:30-9.
    Safety evaluation of zeaxanthin concentrate (OmniXan™): acute, subchronic toxicity and mutagenicity studies.[Pubmed: 24964014 ]
    The available evidence suggests a beneficial effect of Zeaxanthin against the progression of age-related macular degeneration (AMD). The objective of the present study was to investigate potential adverse effects of OmniXan™, a RR-Zeaxanthin (65%) enriched product obtained from paprika (Capsicum annum fruits) in subchronic toxicity and mutagenicity studies.
    METHODS AND RESULTS:
    The oral LD50 of OmniXan(TM) in rats was greater than 2000 mg/kgbody weight (bw)/day. For the subchronic toxicity study, Wistar rats (10/sex/group) were gavaged daily with Zeaxanthin concentrate at doses of 0, 4, 40 and 400 mg/kg bw/day for 90-days. No treatment related clinical signs and mortalities observed. Similarly, no treatment related toxicologically significant changes in body weight, feed consumption; ophthalmoscopic examination, neurological examination, hematology, urine analysis and organ weights were observed. Statistically significant changes observed in some clinical chemistry parameters were considered toxicologically and biologically insignificant and nonadverse. Macroscopic and microscopic examinations did not reveal treatment-related abnormalities.
    CONCLUSIONS:
    The results of mutagenicity testing using Salmonella typhimurium did not reveal any genotoxicity. The no observed-adverse-effect level (NOAEL) for Zeaxanthin concentrate (OmniXan(TM)) was determined as 400 mg/kg bw/day, the highest dose tested. The findings of this subchronic toxicity and mutagenicity studies support safety of Zeaxanthin concentrate.
    Nutr Rev. 2014 Sep;72(9):605-12.
    Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan.[Pubmed: 25109868]
    The relationship between lutein and Zeaxanthin and visual and cognitive health throughout the lifespan is compelling. There is a variety of evidence to support a role for lutein and Zeaxanthin in vision. Lutein's role in cognition has only recently been considered. Lutein and its isomer, Zeaxanthin, are taken up selectively into eye tissue.
    METHODS AND RESULTS:
    Lutein is the predominant carotenoid in human brain tissue. Lutein and Zeaxanthin in neural tissue may have biological effects that include antioxidation, anti-inflammation, and structural actions. In addition, lutein and Zeaxanthin may be protective against eye disease because they absorb damaging blue light that enters the eye. In pediatric brains, the relative contribution of lutein to the total carotenoids is twice that found in adults, accounting for more than half the concentration of total carotenoids. The greater proportion of lutein in the pediatric brain suggests a need for lutein during neural development as well. In adults, higher lutein status is related to better cognitive performance, and lutein supplementation improves cognition.
    CONCLUSIONS:
    The evidence to date warrants further investigation into the role of lutein and Zeaxanthin in visual and cognitive health throughout the lifespan.
    J Ocul Pharmacol Ther. 2014 Sep;30(7):559-66.
    Lutein and zeaxanthin toxicity with and without brilliant blue in rabbits.[Pubmed: 24901374]
    To evaluate the safety profile of solutions containing lutein and Zeaxanthin alone or associated with brilliant blue (BB).
    METHODS AND RESULTS:
    Twenty-eight New Zealand rabbits were used to evaluate 4 concentrations of the various dye solutions: 0.5% lutein/Zeaxanthin; 0.5% lutein/Zeaxanthin associated with 0.0125% BB; 0.3% lutein/Zeaxanthin associated with 0.025% BB; and 0.25% lutein/Zeaxanthin associated with 0.05% BB. The pHs of the dye solutions ranged from 6.5 to 7.2 and the osmolarities from 280 to 320 mOsm/mL. Each rabbit had 0.1 mL of one of the dyeing solutions injected into the vitreous cavity of the right eye, while balanced salt solution (BSS) was injected into the left eye as the control. Scotopic electroretinography responses were recorded in all eyes at different time points. The animals were sacrificed at 1 and 7 days after injection; the eyes were analyzed by light and transmission electron microscopy. No significant (P>0.05) differences were seen in the a- and b-wave amplitudes among groups at any given point in time. Light and electron microscopy findings showed no significant abnormalities either, and were similar to the histological findings after intravitreal BSS injection.
    CONCLUSIONS:
    Lutein and Zeaxanthin alone or in association with BB showed a good safety profile in this experimental model.
    Carasinol D

    Catalog No: CFN95044
    CAS No: 1072797-66-0
    Price: $333/5mg
    6''-O-acetylsaikosaponin A

    Catalog No: CFN95086
    CAS No: 64340-46-1
    Price: $268/10mg
    7-(4-hydroxy-3-methoxyphenyl)-1-phenylhept-4-en-3-one (DPHB)

    Catalog No: CFN95139
    CAS No: 79559-60-7
    Price: $268/20mg
    (3S,5S,E)-1,7-Diphenylhept-1-ene-3,5-diol

    Catalog No: CFN95195
    CAS No: 87095-75-8
    Price: $318/5mg
    [(1(10)E,2R,4R)]-2-Methoxy-8,12-epoxygemacra-1(10),7,11-trien-6-one

    Catalog No: CFN95198
    CAS No: 75412-95-2
    Price: $318/10mg
    Apigenin 4'-O-(2'',6''-di-O-E-p-coumaroyl)glucoside

    Catalog No: CFN95276
    CAS No: 71781-79-8
    Price: $318/10mg
    Physalin X

    Catalog No: CFN95329
    CAS No: 72497-31-5
    Price: $318/5mg
    New compound 13

    Catalog No: CFN95374
    CAS No: N/A
    Price: $318/5mg
    Oxytroflavoside A

    Catalog No: CFN95463
    CAS No: 1391144-80-1
    Price: $318/5mg
    Quercetin-3-O-[alpha-L-rhamnose-(1->2)-beta-D-glucopyranosyl]-5-O-beta-D-glucopyranoside

    Catalog No: CFN95506
    CAS No: 1309795-36-5
    Price: $318/5mg